We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Biomarkers Predict Long-Term Kidney Function After Acute Kidney Injury

By LabMedica International staff writers
Posted on 27 Oct 2021
Print article
Image: Plasma biomarkers measured three months after hospitalization demonstrate utility in assessing AKI patients for long-term CKD risk (Photo courtesy of National Kidney Foundation)
Image: Plasma biomarkers measured three months after hospitalization demonstrate utility in assessing AKI patients for long-term CKD risk (Photo courtesy of National Kidney Foundation)
Acute kidney injury (AKI), previously called acute renal failure (ARF), is a sudden decrease in kidney function that develops within seven days, as shown by an increase in serum creatinine or a decrease in urine output, or both.

AKI may lead to a number of complications, including metabolic acidosis, high potassium levels, uremia, changes in body fluid balance, and effects on other organ systems, including death. People who have experienced AKI are at increased risk of developing chronic kidney disease in the future.

Medical Scientists at the Royal Derby Hospital (Derby, UK) and their colleagues evaluated a number of new blood tests in people who have had AKI, aiming to improve the ability to assess the risk of new or progressive kidney disease. Among a panel of 11 biomarkers tested, a combination of the most promising were identified, comprising Soluble Tumor Necrosis Factor Receptor (sTNFR)1, sTNFR2, cystatin C and eGFR. A total of 500 patients were studied that included adults from a single clinical center who developed AKI, and survived until three years after the hospitalization during which AKI occurred. Participants included those with and without pre-existing chronic kidney diseases (CKD).

The investigators reported that soluble tumor necrosis factor receptor 1 (sTNFR1), sTNFR2, cystatin C, neutrophil gelatinase-associated lipocalin (NGAL), three-month eGFR and urine albumin:creatinine ratio (ACR) were independently associated with kidney disease progression and were more important than AKI severity or duration. A multivariable model containing sTNFR1, sTNFR2, cystatin C and eGFR discriminated between those with and without kidney disease progression (AUC 0.79, 95% CI 0.7-0.83). Optimizing the cut-point to maximize utility as a ‘rule-out’ test to identify those at low risk increased the sensitivity of the model to 95% and its negative predictive value to 92%.

The authors concluded that a panel of plasma biomarkers measured 3-months after discharge from a hospitalization complicated by AKI provides potential opportunity to identify patients who are at very low risk of incident or worsening CKD. Further study is required to determine its clinical utility through independent prospective validation. The study was published on October 12, 2021 in the American Journal of Kidney Diseases.

Related Links:
Royal Derby Hospital

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis
New
Silver Member
Verification Panels for Assay Development & QC
Seroconversion Panels

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.